Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy

Basit Öğe Kaydı
dc.contributor.authorKaya, Ali O.
dc.contributor.authorCoskun, Ugur
dc.contributor.authorOzkan, Metin
dc.contributor.authorSevinc, Alper
dc.contributor.authorYilmaz, Ahmet U.
dc.contributor.authorGumus, Mahmut
dc.contributor.authorUnal, Olcun U.
dc.date.accessioned2024-04-24T17:14:28Z
dc.date.available2024-04-24T17:14:28Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: We retrospectively evaluated the efficacy and toxicity of paclitaxel plus doxorubicin as a second-line treatment in patients with urothelial carcinoma, who had not responded to a prior platinum plus gemcitabine combination. Patients and Methods: All patients received intravenous infusions of paclitaxel (175 mg/m(2)/h) and doxorubicin (50 mg/m(2)/30 min) on day 1. Chemotherapy courses were repeated every 21 days. Results: The median follow-up duration was 13.5 months (range 2.8-22.4 months). Complete and partial responses were observed in 2 (5.6%) and 10 (27.8%) patients, respectively. Median overall survival was 8.9 months (95% confidence interval (CI): 6.2-11.6). Median time to progression was 3.8 months (95% CI: 2.7-4.8). The most common hematologic toxicities were neutropenia (n = 21, 58.3%), thrombocytopenia (n = 10, 27.8%), and anemia (n = 9, 25%). The most common non-hematologic toxicities consisted of fatigue (n = 15, 41.7%), nausea/vomiting (n = 13, 36.1%), peripheral neuropathy (n = 11, 30.6%), and mucositis (n = 6, 16.7%). Dose reductions by 25-35% were performed in 6 (16.7%) patients because of grade 3/4 toxicity. Anthracycline-related heart failure did not occur. Conclusion: 3-weekly courses of cyclic paclitaxel plus doxorubicin were found to be effective and tolerable in patients with urothelial carcinoma, who had not responded to prior platinum- and gemcitabine-based chemotherapy.en_US
dc.identifier.doi10.1159/000342674
dc.identifier.endpage580en_US
dc.identifier.issn0378-584X
dc.identifier.issn1423-0240
dc.identifier.issue10en_US
dc.identifier.pmid23038228
dc.identifier.scopus2-s2.0-84867246214
dc.identifier.scopusqualityQ4
dc.identifier.startpage576en_US
dc.identifier.urihttps://doi.org/10.1159/000342674
dc.identifier.urihttps://hdl.handle.net/11468/17971
dc.identifier.volume35en_US
dc.identifier.wosWOS:000309666500005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOnkologie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPaclitaxelen_US
dc.subjectDoxorubicinen_US
dc.subjectAdvanced Urothelial Carcinomaen_US
dc.subjectSecond-Line Therapyen_US
dc.titlePaclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapyen_US
dc.titlePaclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu